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Blockers of the renin–angiotensin–aldosterone system (RAAS), that is, renin inhibitors, ACE inhibitors, an-
giotensin (Ang) II type 1 (AT1) receptor antagonists, and 
mineralocorticoid receptor (MR) antagonists, are a cor-
nerstone in the treatment of hypertension. At first sight, 
their mechanism of action seems simple: they reduce the 
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(Ang)-converting enzyme (ACE) inhibitors, Ang II type 1 receptor antagonists, and mineralocorticoid receptor 
antagonists, are a cornerstone in the treatment of hypertension. How exactly they exert their effect, in particular 
in patients with low circulating RAAS activity, also taking into consideration the so-called Ang II/aldosterone 
escape that often occurs after initial blockade, is still incompletely understood. Multiple studies have tried to 
find parameters that predict the response to RAAS blockade, allowing a personalized treatment approach. 
Consequently, the question should now be answered on what basis (eg, sex, ethnicity, age, salt intake, baseline 
renin, ACE or aldosterone, and genetic variance) a RAAS blocker can be chosen to treat an individual patient. 
Are all blockers equal? Does optimal blockade imply maximum RAAS blockade, for example, by combining 
≥2 RAAS blockers or by simply increasing the dose of 1 blocker? Exciting recent investigations reveal a range 
of unanticipated extrarenal effects of aldosterone, as well as a detailed insight in the genetic causes of primary 
aldosteronism, and mineralocorticoid receptor blockers have now become an important treatment option for 
resistant hypertension. Finally, apart from the deleterious ACE-Ang II-Ang II type 1 receptor arm, animal studies 
support the existence of protective aminopeptidase A-Ang III-Ang II type 2 receptor and ACE2-Ang-(1 to 7)-
Mas receptor arms, paving the way for multiple new treatment options. This review provides an update about all 
these aspects, critically discussing the many controversies and allowing the reader to obtain a full understanding 
of what we currently know about RAAS alterations in hypertension.  (Circ Res. 2015;116:960-975. DOI: 
10.1161/CIRCRESAHA.116.303587.)
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formation or block the effects of Ang II and aldosterone, 
thereby preventing the deleterious cardiovascular effects 
of these 2 compounds. Logically, they should then be par-
ticularly applied in patients with high RAAS activity, as 
measured in blood plasma. However, it is now well accept-
ed that they are also effective in patients with medium-to-
low RAAS activity. Moreover, after an initial suppression/
blockade of Ang II/aldosterone, the plasma levels of these 
2 compounds often return to normal or even rise above 
pretreatment levels: the so-called Ang II/aldosterone es-
cape.1,2 Yet, remarkably, the RAAS blocker effect remains, 
at least partially. These puzzling observations have led to 
the concept of a local RAAS in various organs, that is, the 
real site of action of RAAS blockers. According to some 
investigators, this local RAAS occurs entirely intracellu-
lar (intracrine RAAS).3 In addition, during RAAS blocker 
application, an upregulation occurs of multiple angioten-
sin metabolites, which may exert actions of their own and 
possibly even contribute to the beneficial effects of RAAS 
blockade. Examples of these protective (vasodilator) path-
ways include the angiotensinase A-Ang III-Ang II type 2 
(AT2) receptor pathway and the ACE2-Ang-(1–7)-Mas re-
ceptor pathway (Figure 1). Further knowledge in this area 
might lead to new drugs.
For a long time, it was thought that the more RAAS block-
ade, the better, also in view of the above described Ang II/
aldosterone escape. However, dual RAAS blockade trials have 
now shown that this is not necessarily the case and that the 
consequences of too much RAAS suppression (hyperkalemia, 
renal dysfunction, and hypotension) may overrule the benefi-
cial effects of this approach. A variety of RAAS differences 
exists between men and women, and between black and white 
people, with men and white people generally having higher 
renin levels. This does not necessarily translate into similarly 
elevated aldosterone levels, and in fact, patients with high 
aldosterone-to-renin ratios (ARR) can be identified, which 
respond particularly well to MR blockers. A wide range of 
mutations has recently been identified that gives rise to selec-
tive aldosterone rises.
This review will critically discuss all the above aspects. 
What is a local RAAS? What are the local actions of Ang II 
in the vessel wall? What are the (genetic) determinants of a 
solid response to a RAAS blocker? Is there such a thing as too 
much RAAS blockade? Are all RAAS blockers equally good? 
Are the sex- and ethnicity-related RAAS differences clinically 
relevant? What about the recent developments in primary hy-
peraldosteronism and the extrarenal effects of aldosterone? 
Finally, can we expect new RAAS drugs?
What Is a Local RAAS?
Originally, when developing the concept of local RAAS, it 
was proposed that all components required to generate Ang II, 
and aldosterone locally are synthesized at multiple sites in the 
body, allowing their generation to occur independently from 
the classical sites of RAAS component synthesis: the kidney 
(renin), liver (angiotensinogen), and adrenal (aldosterone). In 
addition, a wide variety of nonclassical enzymes, in particular 
chymase, was suggested to contribute to Ang II generation as 
well.4 Some, if not all, RAAS components were even detected 
in cells, leading to the concept of an intracrine RAAS, involv-
ing the intracellular generation of Ang II acting on intracel-
lular (nuclear) receptors.3
Finally, the confusing observation that humans have large 
amounts of prorenin, the inactive precursor of renin, has led 
to a search for prorenin receptors that bind and activate pro-
renin locally, thus offering an explanation of why we have so 
much prorenin (its concentrations are ≤100 times of renin): it 
would then function as a regulator of tissue Ang generation. 
One such candidate, the so-called (pro)renin receptor ((P)RR), 
which binds both renin and prorenin, has received much at-
tention during the last decade.5 Unfortunately, the concentra-
tions of renin/prorenin (together denoted here as (pro)renin) 
that are required to result in receptor binding are far above 
the normal (patho)physiological levels, and transgenic rodents 
overexpressing either the (P)RR or prorenin did not reveal any 
evidence for (pro)renin–(P)RR interaction in vivo, that is, 
their Ang II levels were unaltered.6 Moreover, (P)RR knock-
out (KO), unlike renin KO, is lethal.7 This may relate to (P)
RR’s association with vacuolar H+-ATPAse, a crucial enzyme 
found in virtually every cell type that is important for the 
acidification of intracellular compartments. Therefore, (P)RR 
research is now focusing on its functions beyond the RAAS 
because the (P)RR may not be a part of the RAAS after all, 
except perhaps in organs where (pro)renin is synthesized lo-
cally (allowing high local concentrations that result in recep-
tor activation).
Similarly, the view of chymase as a major Ang I-II convert-
ing enzyme is most likely an in vitro artifact related to the 
measurement of Ang II formation in tissue homogenates (par-
ticularly from the human heart), where chymase is no longer 
in its intracellular storage sites.4 Careful measurements of Ang 
II in ACE KO mice did not support the concept that chymase 
is an Ang I-II converting enzyme in vivo.8 In fact, renin and 
angiotensin measurements are hampered by multiple techni-
cal difficulties, particularly in tissues, and because many of 
Nonstandard Abbreviations and Acronyms
APA aldosterone-producing adenoma
ARR aldosterone-to-renin ratio
AT1 angiotensin II type 1
AT2 angiotensin II type 2
BP blood pressure
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GPER G-protein-coupled estrogen receptor-1
KO knockout
MR mineralocorticoid receptor
NO nitric oxide
PA primary aldosteronism
(P)RR (pro)renin receptor
RAAS renin–angiotensin–aldosterone system
SHR spontaneously hypertensive rat
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the original conclusions on tissue RAAS were based on such 
nonideal measurements, they need to be viewed with care. 
For instance, the original observations that renin and Ang II 
are unaltered after a bilateral nephrectomy turned out not to 
be true.9 Moreover, there is no intracellular Ang II in AT re-
ceptor KO mice.10 Clearly therefore, there is only one renin 
source in the body (the kidney), angiotensin generation oc-
curs extracellularly (in blood, interstitial fluid, and on the cell 
surface), and any Ang II present in cells accumulated there 
after its internalization after AT receptor binding. Selective 
KO of renal angiotensinogen revealed that the concept of re-
nal angiotensinogen contributing to renal Ang II production 
was not true: all renal Ang II generation depended on hepatic 
angiotensinogen.11 Although similar conclusions have been 
reached in the heart,12 local angiotensinogen synthesis has 
been claimed in the vessel wall,13 and adipocytes are generally 
believed to generate angiotensinogen.14 Surprisingly, adipo-
cyte angiotensinogen deficiency did not affect plasma angio-
tensinogen levels, but greatly reduced circulating Ang II under 
high fat diet conditions.14 Additional studies, inducing selec-
tive KO of adipocyte angiotensinogen, hepatic angiotensino-
gen, or both are required to fully understand the contribution 
of adipocyte angiotensinogen to Ang II production. Also with 
regard to aldosterone, the original reports on its generation in 
heart, vessel wall, and kidney were not confirmed on careful 
re-examination of the measurements after adrenalectomy and 
in isolated organs.15–17
Summarizing, the current view is that Ang II generation in tis-
sues does occur (in fact, >90% of tissue Ang II is synthesized 
locally and not taken up from plasma18,19), but depends on renal 
renin and largely, if not completely, on hepatic angiotensinogen. 
Both diffuse into the interstitium, allowing local Ang II genera-
tion to take place in that compartment with the help of membrane-
bound, ubiquitously present ACE (Figure 2). This Ang II rapidly 
binds to AT receptors, and such binding is followed by internal-
ization, explaining why tissue Ang II levels are often high and 
correlate closely with tissue AT receptor density.20 Aldosterone is 
exclusively adrenal-derived. To what degree prorenin has a role, 
beyond the (P)RR, remains to be determined.
Local Effects of Ang II in the Vessel Wall
When focusing on the vessel wall, it is well-established that 
activation of AT1 receptors induces vasoconstriction, endo-
thelial dysfunction, inflammation, growth, and remodeling, 
whereas AT2 receptors are believed to counteract these ef-
fects (Figure 3). However, the latter is not a uniform finding, 
Figure 1. New and existing drugs interfering with 
the renin–angiotensin (Ang) system cascade. 
Classically, interference occurs at the level of renin, 
angiotensin-converting enzyme (ACE), the Ang II 
type 1 (AT1) receptor (R), or the mineralocorticoid 
receptor (MR), with renin inhibitors, ACE 
inhibitors AT1 receptor blockers (ARBs) or MR 
antagonists. Novel enzyme inhibitors now target 
aminopeptidase A (APA), which generates Ang III 
(=Ang-[2–8]) from Ang II (=Ang-1–8)), or aldosterone 
synthase (CYP11B2). Activators of ACE2 (XNT 
and diminazene), which generates Ang-(1–7) from 
Ang II, were recently found to act equally well in 
ACE2 knockout (KO) animals, thus questioning 
their mechanism of action. Numerous agonists for 
both the AT2 receptor and Mas receptor are being 
developed. Aminopeptidase N (APN) degrades 
Ang III to Ang IV (=Ang-(3–8)), which may act on 
the AT4 receptor, also known as insulin-regulated 
aminopeptidase (IRAP).
Figure 2. Circulating versus tissue renin–angiotensin (Ang) 
system. Circulating renin is kidney-derived, and circulating 
angiotensinogen originates in the liver. Angiotensin-converting 
enzyme (ACE) is located on endothelial cells. Ang II generated 
in the circulation will diffuse to tissues to bind to its main 
receptor (the Ang II type 1 receptor, AT1R) to exert effects. In 
addition, circulating renin and angiotensinogen might also 
diffuse to tissue sites (eg, the interstitial space) and generate, 
with the help of tissue ACE, Ang II locally. In a limited number 
of tissues, renin’s precursor prorenin is produced locally. 
To what degree such prorenin, for example, following its 
conversion to renin, contributes to local angiotensin production 
remains unknown. Although local production has also been 
claimed for angiotensinogen, in particular in the kidney, current 
evidence does not support a functional role for kidney-derived 
angiotensinogen because the renal Ang II levels in renal 
angiotensinogen knockout (KO) mice are identical to those in 
wild-type mice.11 Locally generated Ang II rapidly binds to AT1 
and AT2 receptors, the former being followed by internalization. 
This explains the intracellular presence of Ang II, as well as the 
high tissue levels of Ang II in high AT1 receptor-density organs like 
the adrenal (Illustrated Credit: Ben Smith).
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and under certain conditions, for example, in the spontane-
ously hypertensive rat (SHR), AT2 receptors may become 
AT1 receptor-like.21,22 The mechanism behind this pheno-
type change is unclear, but most likely involves a difference 
in location (endothelial cell (EC) versus vascular smooth 
muscle cell (VSMC)) and heterodimerization with AT1 re-
ceptors. Therefore, whether upregulation of AT2 receptors 
under pathological conditions is always beneficial remains 
unknown.23 Similar opposing findings with regard to AT2 re-
ceptor function have been made in the heart.24 Of interest, 
Figure 3. Effects of angiotensin (Ang) II, via its Ang II type 1 and 2 (AT1 and AT2) receptors (AT1R, AT2R) on vascular remodeling 
and constriction/vasodilation. Transforming growth factor-β (TGF-β) signaling by the TGF-β receptor (via the Smad2/3 pathway) 
and mitogen-activated protein kinase (MAPK) activation after AT1 receptor stimulation jointly regulate the transcription of target genes 
(eg, matrix metalloproteinase, MMP; plasminogen-activator inhibitor-1, PAI-1; connective tissue growth factor, CTGF) that result in 
proliferation, extracellular matrix production/fibrosis, differentiation, and inflammation. AT1 receptor stimulation additionally upregulates 
NAD(P)H oxidase (NOX), thereby increasing reactive oxygen species (ROS) formation, which also regulates the transcription of the above-
mentioned target genes. AT2 receptor stimulation inhibits this pathway by blocking MAPK. AT2 receptors also induce vasorelaxation 
by activating NO synthase (NOS). This may counteract the constrictor effects of AT1 receptor stimulation (mediated by the inositol 
trisphosphate [IP3]-Ca
2+ and diacylglycerol [DAG]-protein kinase C [PKC] pathways). Under pathological condition, ROS uncouple NOS, 
thereby diminishing NO production and potentially facilitating ROS formation by NOS.
Angiotensinogen
Angiotensin I
NOS
ROS
Renin
Angiotensin II
ACE
Angiotensin-(1-9)
Angiotensin-(1-7)
ACE
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ACE2
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Prorenin
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Figure 4. Vasoconstrictor–vasorelaxant balance 
of the renin–angiotensin–aldosterone system 
(RAAS) in relation to sex hormone status in men 
and pre- and postmenopausal women. The figure 
highlights X-chromosome-located RAAS genes, 
including the (pro)renin receptor ((P)RR) gene. The 
current view is that its relationship with the RAAS 
may be limited to (pro)renin-synthesizing organs, 
where (pro)renin is sufficiently high to result in 
significant receptor binding.
 by guest on M
arch 2, 2017
http://circres.ahajournals.org/
D
ow
nloaded from
 
964  Circulation Research  March 13, 2015
post myocardial infarction, a moderate cardiac AT2 recep-
tor overexpression in transgenic mice protected against mal-
adaptive remodeling and dysfunction, whereas a massive, 
9-fold overexpression did not yield such positive effects.25 
Thus, also the degree of overexpression may determine AT2 
receptor function.
Wide attention has been paid to the fact that increased 
vascular Ang II levels increase NAD(P)H oxidase activ-
ity in EC, adventitial cells, and VSMC, thereby stimulat-
ing reactive oxygen species formation in the vessel wall.26 
Reactive oxygen species products like superoxide and 
H2O2 subsequently activate multiple signaling pathways, 
involving mitogen-activated protein kinases, tyrosine ki-
nases, phosphatases, calcium channels, and redox-sensitive 
transcription factors,26,27 together resulting in cell growth, 
expression of proinflammatory genes (eg, transforming 
growth factor-β), and the production of extracellular ma-
trix proteins, like collagen, elastin, fibrillin, fibronectin, 
and proteoglycans. The latter production usually involves 
a phenotype switch in VSMC, from contractile to prolifera-
tive/synthetic. In addition, there is an imbalance between 
apoptosis and growth.
Recent evidence supports a role for the Ang II-
transforming growth factor-β axis in aneurysm 
development.28,29 Infusion of Ang II in atherosclerotic apo-
lipoprotein E- or LDL receptor KO mice provides an exper-
imental model for the most common type of aneurysm, the 
abdominal aortic aneurysm. Thoracic aortic aneurysms are 
less common and often have a genetic background, involv-
ing mutations in the above-mentioned extracellular matrix 
proteins and transforming growth factor-β. A well-known 
example is Marfan’s syndrome. Losartan was shown to be 
effective in adults with this syndrome,30 and animal data 
suggest that this effect involves AT2 receptor stimulation 
rather than AT1 receptor blockade.31 Both the transform-
ing growth factor–β-induced canonical (pSmad2/3) and 
noncanonical (mitogen-activated protein kinases) signal-
ing pathways are upregulated in thoracic aortic aneurysms 
mouse models, and their suppression may underlie the ef-
fectiveness of AT1 receptor blockade in these models.31,32 
As a consequence of these exciting new findings, multiple 
trials now investigate the effectiveness of RAAS block-
ers in Marfan’s syndrome.29 An important issue will be to 
what degree ACE inhibition (which does not result in AT2 
receptor stimulation) differs from AT1 receptor antagonism. 
One of these trials was recently published.33 Involving 608 
Marfan patients (age 6 months to 25 years), it did not show 
superiority of losartan versus the β-adrenergic antagonist 
atenolol. Beta-adrenergic antagonists are the current stan-
dard therapy in Marfan patients. Here it should be realized 
that such drugs also suppress renin release. The investiga-
tors applied a relatively high dose of atenolol and a low 
dose of losartan, and there was no placebo group. Moreover, 
treatment was started in most cases at an advanced stage of 
the disease. Thus, on the basis of this study, it can be con-
cluded that losartan is a safe alternative for a β-adrenergic 
antagonist, but not yet whether (at the appropriate dose and 
perhaps when given at an earlier stage of development) it 
might be better.
Sex-Related Aspects
Physiologically, the 2 major differences between men and 
women are (1) different levels of sex hormones (testosterone 
versus estrogen) and (2) the sex chromosome complement 
(XY versus XX). The combination of a different hormonal 
milieu and different genes located on the sex chromosomes 
results in a transcriptome with a sex-specific and sex-biased 
expression. This leads to a marked sexual dimorphism in 
anatomy, physiology, and metabolism, but also extends to sex 
differences in blood pressure (BP), sensitivity to Ang II, and 
severity of cardiovascular disease.34
Sex Hormones
Premenopausal women have a lower BP in comparison to 
age-matched men (≈10 mm Hg for systolic BP and ≈5 mm Hg 
for diastolic BP). Because this sexual dimorphism in BP 
manifests itself during adolescence and disappears after the 
menopause, it is logical to assume a role for sex hormones. 
Testosterone binds to the androgen receptor, whereas estrogen 
(17β-estradiol) stimulates the estrogen receptor α and β, as 
well as the G-protein-coupled estrogen receptor-1 (GPER). 
These receptors mediate both genomic and nongenomic ef-
fects. The former involve interaction of the hormone–receptor 
complex with nuclear DNA, modulating the transcription 
of sex hormone-responsive genes (taking hours), whereas 
the latter involves signaling cascades resulting in effects 
within seconds-minutes. In the case of estrogen, this results 
in endothelium-dependent and -independent dilator effects 
through nitric oxide (NO), cGMP, cAMP, and K+-channels.35 
Testosterone is believed to counteract such endothelium-de-
pendent vasorelaxation and to exert direct constrictor effects35; 
the BP-lowering effects after castration confirmed this view.36
In addition, sex hormones affect RAAS components and 
modulate Ang II sensitivity. Indeed, estrogens increase an-
giotensinogen, ACE2, AT2 receptor density, and endothe-
lial NO synthase, whereas they decrease renin, ACE, AT1 
receptor density, and the NADPH oxidase subunits Nox1 
and Nox2 (Figure 4).37,38 These alterations are suggestive 
for an upregulation of ACE2-derived angiotensin-(1–7) for-
mation, enhanced AT2 receptor stimulation and NO release, 
combined with reduced reactive oxygen species formation; 
in other words, they favor the vasodilator arm of the RAAS 
(see also below). Indeed, low doses of Ang II even decreased 
BP in female (but not male) rats,39 and higher doses exerted 
larger BP-increasing effects in males than in females, whereas 
gonadectomy reversed these effects.40 Testosterone increases 
renin, ACE, and AT1 receptors and downregulates AT2 recep-
tors, thereby favouring the constrictor arm. There are no clear 
differences in aldosterone levels between men and women.41 
In postmenopausal women, the balance will shift toward the 
vasoconstrictor arm, unless they receive hormone replacement 
therapy.37
Sex Chromosomes
In most mammals, males are heterogametic, possessing 1 X 
and 1 Y chromosome, whereas females are homogametic with 
2 X chromosomes. This characteristic plays a fundamental 
role in the sexual dimorphism through variances in gene ex-
pression. Evolutionary, sex chromosomes have evolved out of 
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a pair of matched autosomes, which eventually lost the abil-
ity to recombine because of an accumulation of male-specific 
functions on one chromosome and degradation of nonrecom-
bining regions.42 Genes mapped to the Y chromosome play an 
important role in sex development, testosterone production, 
and fertility.
A limited number of studies suggest that sex chromosomes 
influence BP and regulate RAAS genes. Introgression of the 
YSHR chromosome from the SHR strain on a normotensive 
WKY background resulted in a ≈20 mm Hg BP difference 
versus rats, where the normotensive YWKY chromosome was 
introgressed on the SHR background.43 The four core geno-
type mouse model involves the deletion of the sex-determin-
ing region Y (Sry) from the Y chromosome and the insertion 
of the Sry transgene onto an autosome, thereby resulting in 
XY–Sry males.44 Crossing these mice to normal XX females 
will result in 4 genotypes, XX gonadal males and females, 
as well as XY gonadal males and females. Interestingly, Ang 
II induced a larger BP rise in gonadectomized 4 core geno-
type mice with an XX genotype than in their XY counter-
parts independent of prior sex hormone status and gonadal 
phenotype.45 It is tempting to speculate that this mechanism 
underlies the relatively rapid increase in BP observed in 
postmenopausal women.46 The Sry gene family is known 
to upregulate angiotensinogen, renin, and ACE, whereas 
it downregulates ACE2 in vitro.36 In addition, the (P)RR, 
ACE2, Nox1, Nox2, and the AT2 receptor are mapped to the 
X chromosome (Figure 4). Although dosage-compensation 
takes place in women by an epigenetic mechanism called 
X-inactivation to prevent a lethal dose of X-mapped genes, 
several genes (15% to 20%) have been reported to escape 
X-inactivation47 and contribute to sex differences because of 
a higher expression in XX than XY cells.48 Such escape also 
applies to the (P)RR,49,50 but the physiological relevance of 
this observation is still unknown.
Consequences for Treatment?
It is well-accepted that premenopausal women are protected 
from the development of cardiovascular disease in compari-
son to age-matched men.51 Obviously, having a higher BP for 
≤4 to 5 decades, even when modest, will have consequences. 
As discussed earlier, animal data support a major role for the 
RAAS in sex-related differences. Yet, there are no sex-specific 
recommendations for antihypertensive therapy, nor is there 
currently any evidence that men and women respond differ-
ently to RAAS blockers. One retrospective study in patients 
with heart failure claimed a higher efficacy of ACE inhibitors 
in males and of AT1 receptor blockers in females.52 Although 
this potentially supports the importance of AT2 receptor stimu-
lation in women, large prospective studies are warranted to 
confirm such claims.
Determinants of RAAS Blocker Response and 
the Degree of Blockade
Prediction of RAAS Blocker Response
Although sex, as discussed earlier, is not an established de-
terminant of RAAS blocker response, multiple attempts 
have been made to predict the response to a RAAS blocker 
on the basis of alternative parameters. Genetic variation has 
been evaluated, usually by studying single nucleotide poly-
morphisms in RAAS genes in a retrospective manner in large 
clinical trials.53,54 Emphasis has been on the ACE insertion/
deletion polymorphism.55 Unfortunately, the effects were 
small and difficult to replicate, and, given the nonexistence of 
large prospective studies to further evaluate these findings, at 
this stage, there is no useful genetic information that can be 
applied to the individual patient to help choosing a specific 
RAAS blocker.
Along the same lines, it has been argued that patients with 
high RAAS activity (like patients with bad RAAS gene vari-
ants) should preferably be treated with RAAS blockers. Such 
patients should then be selected on the basis of their high renin, 
ACE, and aldosterone levels. Ang II levels might also be use-
ful, but given the technical difficulties to measure this RAAS 
component, this is currently not feasible. The background of 
this concept is that patients with high baseline RAAS activity 
have a higher risk to develop cardiovascular disease. Indeed, 
retrospective analyses of patient populations in clinical trials 
in whom baseline renin measurements were available support 
that high renin levels are indicative of future cardiovascular 
disease and death, particularly in patients with kidney dys-
function, and hypertension.56–59 Remarkably, this relationship 
was not affected by the use of RAAS blockers, which, through 
interference with the negative feedback loop between Ang II 
and renin, increase renin release. Obviously, renin measure-
ments, when based on activity, will be disturbed by the use 
of renin inhibitors, and thus during such treatment only mea-
surements of plasma renin concentration, and not plasma re-
nin activity, will give an indication of the true renin levels. In 
addition, salt intake affects renin secretion, with patients on a 
low salt diet displaying higher renin levels. Preferably there-
fore, when considering pretreatment renin levels as a treat-
ment determinant, salt intake should be taken into account.
Laragh and Sealey distinguish a low renin, sodium volume–
dependent form of essential hypertension and a medium-to-
high renin form of hypertension.60 The former occurs whenever 
body sodium content increases beyond the point where plasma 
RAAS activity is turned off, whereas the latter occurs when 
too much renin is secreted relative to the body sodium content. 
Antihypertensive treatment should then be aimed at reducing 
either body salt and volume content (diuretics, calcium antag-
onists) or RAAS activity (RAAS blockers and β-adrenergic 
antagonists; the latter suppress renin release). Retrospective 
analyses of BP trials confirmed this concept.61,62 In addition, 
Gupta et al observed that African Americans, who on average 
have lower renin levels compared with Caucasians,63 respond-
ed less well to atenolol.64 Yet, others observed either no role for 
baseline renin,65 or at most a weak trend.66–68 Moreover, the BP 
decreases for a given baseline renin level (uncorrected for salt 
intake) varied >40 mm Hg. In addition, a uniform definition of 
high renin (plasma renin activity/plasma renin concentration) 
is not available and clearly complicated by the intake of salt, 
sex, ethnicity, and the use RAAS-affecting drugs.61,65,67 Thus, 
although in general it is probably true that patients with high 
renin levels respond better to RAAS blockers (for instance, 
patients pretreated with a diuretic, which activates the RAAS), 
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the variation in renin is such (not even taking into consider-
ation the additional variation at the tissue level!) that it is of 
limited practical use for the individual patient. Unfortunately, 
the same is true for plasma ACE.69 The use of aldosterone 
measurements will be discussed below.
Desired Degree of RAAS Blockade
Given the Ang II/aldosterone escape during RAAS blocker 
treatment, usually occurring within days-weeks after drug ini-
tiation,70 for many years it was argued that the more blockade, 
the better, to keep the levels of these active components (or 
their activity) low. Nevertheless, early animal studies in SHR71 
had already shown that dual RAAS blockade, particularly un-
der low-salt conditions (when the RAAS is most needed) is 
lethal: it caused a major decrease in BP and severe renal fail-
ure, which were accompanied by massive rises (up to several 
100-fold) in plasma renin and renal renin levels, thereby de-
creasing the angiotensinogen concentration in plasma. These 
deleterious effects of dual RAAS blockade were prevented by 
a high salt diet. Studies in human cardiac tissue, obtained from 
patients undergoing cardiac transplantation or severe heart 
failure patients at the time of left ventricular assist device im-
plantation,72,73 both being treated with (high) RAAS blocker 
doses, revealed that also in the human heart renin levels may 
rise >100-fold, thereby decreasing cardiac angiotensinogen. 
Interestingly, after left ventricular assist device implantation, 
renin levels dropped 10-fold and cardiac angiotensinogen 
levels rose again, thereby allowing a rise in cardiac Ang II 
levels.73 This illustrates the fact that at high renin levels, an-
giotensinogen depletion essentially renders Ang II generation 
impossible.
Taken together, these data illustrate that too much RAAS 
blockade annihilates the capacity of tissues to acutely gen-
erate Ang II when necessary. Particularly in the kidney, this 
may be crucial to preserve glomerular filtration. Recent data 
obtained in salt-depleted healthy volunteers exposed to in-
creasing doses of a new renin inhibitor, VTP-27999, provide 
further evidence for this concept.74 To fully appreciate these 
data, it should be mentioned that renin inhibitors selectively 
accumulate in the kidney, remaining present in renal tissue at 
high levels, even at days-weeks after stopping treatment, when 
plasma levels are undetectable.75,76 It was observed that at the 
highest dose of VTP-27999 tested (600 mg), the drug blocks 
the renal RAAS more effectively than the circulating RAAS. 
Indeed, when stopping drug intake after 10 days of dosing, the 
plasma renin concentration levels at 24 to 72 hours after the 
last dose exceeded the capacity of extrarenal VTP-27999 to 
fully block renin’s enzymatic activity (Figure 5). Therefore, 
even though the intrarenal RAAS is still inhibited at these 
times, extrarenal RAAS activation now occurred, increas-
ing the circulating concentrations of Ang II and aldosterone. 
These findings are reminiscent of the nephrocentric view of 
ACE inhibition noted 25 years ago in patients with conges-
tive heart failure.77 It was asked why the kidneys continue to 
release renin in such patients; the answer being that they do 
everything possible to preserve renal function and glomeru-
lar filtration, apparently at the expense of the hemodynamic 
burden on the heart. Exactly this happened in the VTP-27999 
study, where the kidneys responded to excessive renal RAAS 
suppression by releasing large quantities of renin, resulting in 
elevations of plasma renin activity, Ang II, and aldosterone. 
Such elevated Ang II levels were most likely responsible for 
the (nonsignificant) increase in heart rate observed in the sub-
jects treated with 600 mg VTP-27999. Clearly therefore, renin 
inhibition has an upper limit and more is not always better.
The latter also applies to other types of excessive RAAS 
blockade (eg, when combining an ACE inhibitor and an 
AT1 receptor antagonist): several large dual RAAS blockade 
studies (ONTARGET, ALTITUDE, NEPHRON-D)78–80 in a 
variety of patients all concluded that the adverse effects (hy-
potension, hyperkalemia, and renal dysfunction), all because 
of (renal) Ang II depletion, outweighed the beneficial effects. 
In reaching this conclusion, it should be realized that often 
these patients additionally took β-adrenergic antagonists and 
MR antagonists and thus were in reality not exposed to dual 
but to quadruple RAAS blockade. This led Nussberger and 
Bohlender to conclude that the goal should not be maximal 
but optimal RAAS blockade, guided by regularly measuring 
BP, serum potassium, and creatinine.81
Recent guidelines no longer recommend the combined use 
of ACE inhibitors, AT1 receptor blockers, and renin inhibitors 
in hypertension.82 Most evidence is obviously available for 
the ACE inhibitors. As explained earlier, there is still discus-
sion to what degree the AT2 receptor stimulation during AT1 
receptor blockade is beneficial or harmful. Two recent meta-
analyses show that ACE inhibitors reduce all-cause mortality 
and cardiovascular death in patients with hypertension and 
diabetes mellitus, whereas AT1 receptor blockers do not.83,84 
This may relate to the possibility that AT2 receptor stimulation 
affects the incidence of myocardial infarction85,86 and induces 
apoptosis in intestinal epithelial cells, thereby inducing severe 
gastrointestinal problems.87,88 Additionally, AT2 receptor stim-
ulation activates the bradykinin axis,89 although bradykinin 
accumulation will also occur after ACE inhibition. The exact 
contribution of bradykinin to the beneficial effects of RAAS 
blockade in humans remains to be determined. Nevertheless, 
based on these findings, it is clear that ACE inhibitors should 
be considered as first-line agents in patients with hypertension 
and diabetes mellitus.
Aldosterone
Aldosterone is a steroid hormone produced in the zona glo-
merulosa of the adrenal gland. Like Ang II, aldosterone is an 
effector hormone of the RAAS, principally involved in vol-
ume and BP regulation. Beyond BP, aldosterone has emerged 
as a cardiovascular risk factor promoting cardiovascular and 
renal inflammation, fibrosis, and remodeling. Furthermore, in 
cohort studies of nonhypertensive individuals, higher circulat-
ing aldosterone levels, but still within the physiological range, 
are a risk factor for the development of hypertension.90 With 
regard to hypertension, the importance of aldosterone is large-
ly related to primary aldosteronism and treatment-resistant 
hypertension. The mechanism of action of aldosterone was 
thought to be restricted to its renal genomic effects, causing 
sodium and water retention. More recently, evidence has accu-
mulated for effects of aldosterone on EC and VSMC that may 
or may not be mediated by the MR.91–93 In the first part of this 
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section, we focus on new insights in the potential vascular ef-
fects of aldosterone and the receptors involved. In the second 
part, new developments in the pathogenesis and etiology of 
primary aldosteronism and the role of aldosterone in resistant 
hypertension will be reviewed.
Aldosterone, Aldosterone Receptors, and Sodium 
Channels
Aldosterone is synthesized from cholesterol in the zona glo-
merulosa of the adrenal gland by a series of enzymatic reac-
tions. The final steps of aldosterone synthesis are catalyzed 
by aldosterone synthase encoded by the gene CYP11B2 lo-
cated on chromosome 8q21-22. Classic stimulators of al-
dosterone biosynthesis are Ang II, extracellular potassium 
concentration, and ACTH. Vascular endothelial growth factor 
has recently emerged as a stimulator of aldosterone produc-
tion.94 Stimulation by these factors results in activation of 
aldosterone synthase induced by an increase in intracellular 
calcium concentration.95
Aldosterone classically works in a genomic way through 
the induction and modulation of gene transcription with the 
cytoplasmatic/nuclear MR within the renal cortical collecting 
duct cells as its main target. After binding of aldosterone to the 
MR, causing dissociation of chaperones and formation of MR 
dimers, this complex translocates to the nucleus, resulting in 
increased expression of several intracellular kinases, includ-
ing serum- and glucocorticoid-induced kinase 1, Kirsten Ras 
GTP-binding protein 2A, and WNK4. This process leads to 
Figure 5. The consequences of too much renin inhibition (with the new renin inhibitor VTP-27999), as observed after stopping 
treatment. Normally, the decrease in plasma drug level and renin concentration after stopping run in parallel. However, after a high (600 
mg) dose of VTP-27999 (which, like aliskiren, is known to accumulate in the kidney76), plasma renin suppression lags behind the decline 
in plasma drug decrease, most likely because the renal renin–angiotensin–aldosterone system (RAAS) is still suppressed, thus keeping 
renin release at a (too) high level, which can no longer be suppressed by VTP-27999 in plasma. As a consequence, plasma renin activity, 
Ang II, and aldosterone rise above control levels. In other words, too much renin inhibition, by excessively blocking the renal RAAS, may 
effectively activate extrarenal RAAS activity. Data derived from Balcarek et al.74
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increased expression of the luminal located epithelial sodium 
channel, renal outer medullary K+-channels, and the baso-
laterally located Na+/K+-ATPase.96 Increased renal epithelial 
sodium channel activity promotes renal Na+ reabsorption, re-
sulting in volume expansion and a rise in BP.
Additionally to its expression in renal collecting duct cells, 
the MR is also expressed in ECs and VSMCs.92,93 Important 
new insight in the role of the VSMC-MR has been obtained by 
engineering a mouse with an inducible, selective deletion of 
VSMC-MR.97 In these KO mice, BP at young age is similar as 
in wild-type control mice, but, despite intact renal MR recep-
tors, the age-related rise in BP is attenuated. Furthermore, aged 
VSMC-MR-KO mice have a decreased vascular tone, and the 
aged vessels exhibit decreased contractile responses to throm-
boxane, Ang II, and calcium channel agonists.97 Moreover, these 
mice have an attenuated increase in BP and superoxide produc-
tion to Ang II infusion and a decrease in large-artery stiffness 
after aldosterone salt challenge compared with wild-type mice.98
Several new molecular pathways activated by the inter-
action of aldosterone with the VSMC-MR and contributing 
to vascular remodeling have been described in the past sev-
eral years.98–100 These pathways promote vascular inflamma-
tion, fibrosis and VSMC hypertrophy, and proliferation and 
may contribute to the development of large artery stiffness. 
Although the clinical implication of these pathways requires 
further research, it has already been shown in patients with 
familial hyperaldosteronism type I that cardiac and vascular 
damage may precede the development of hypertension.101
In ECs, aldosterone increases the expression of endothelial 
Na channels in a MR-dependent way that can be blocked by 
spironolactone.102 Increased endothelial Na channel activity in 
combination with a high plasma sodium leads to stiffening of 
the cortex of ECs caused by an increase in sodium influx. A 
direct consequence of this stiffening is a decrease in endo-
thelial NO synthase–mediated NO release.103 Thus, high al-
dosterone in combination with high salt intake may result in 
endothelial dysfunction, which may contribute to a rise in BP 
independent of the renal effects of aldosterone.
Besides its genomic effects mediated by stimulation of the 
MR receptors in the kidney and vasculature, rapid nongenomic 
effects of aldosterone have also been reported.91 These nonge-
nomic effects of aldosterone may be mediated by GPER.91,104 
GPER is a widely distributed receptor, also identified in EC 
and VSMC.105 GPER in cultured EC and VSMC can be stimu-
lated by estrogen but also by aldosterone at picomolar concen-
trations.91 Aldosterone-induced activation of aortic vascular 
ECs via GPER leads to vasodilation as well as to proapoptotic 
and antiproliferative effects.104 These effects of aldosterone 
are blocked by the GPER receptor antagonist G15. Whether 
aldosterone also exerts effects on VSMCs through activation 
of the GPER is uncertain, as GPER expression is no longer 
present when aortic VSMCs are cultured.91 GPER seems to 
play a role in the potentiation of Ang II–induced vasoconstric-
tion by aldosterone because this potentiation could be blocked 
by G15, but not by the MR-antagonist eplerenone.106
Sporadic and Familial Primary Aldosteronism
Primary aldosteronism (PA) is characterized by excessive 
autonomous aldosterone secretion by the adrenal gland. The 
consequent volume expansion and hypertension leads to renin 
suppression, and accordingly the ARR has been advocated as 
a screening test for PA.107 Among hypertensive individuals, the 
prevalence of PA is high, ranging from 4.3% in a primary care 
setting to 9.0% of referred patients and to 20% of those with 
therapy-resistant hypertension.108 We and others have shown 
that the sensitivity of the ARR as a screening test for PA is 
relatively poor, which may relate to the way patients were se-
lected and to overestimation of the true renin concentration 
by the nowadays commonly used direct renin assay (because 
of codetection of prorenin) instead of plasma renin activity 
measurements.109,110
PA can be divided in frequent sporadic and rare familial 
forms. Familial hyperaldosteronism (FH) type 1, also known 
as glucocorticoid-remediable aldosteronism, is an autosomal 
dominant disease caused by a recombination between the 
CYP11B2 and CYP11B1 (the latter being responsible for 
cortisol synthesis) genes, creating a chimeric gene whereby 
the CYP11B1 promotor and CYP11B2 coding sequences are 
juxtaposed. In FH-I, aldosterone synthesis is regulated by 
ACTH rather than by Ang II. Administration of glucocorti-
coids (thereby suppressing ACTH) reduces aldosterone levels, 
and the lowest dose of glucocorticoids normalizing BP is the 
treatment of choice. The cause of FH-II has yet to be iden-
tified. FH-II is diagnosed if ≥2 members of one family are 
affected. Adenomas as well as bilateral hyperplasia may un-
derlie FH-II. The first family with FH-III has been described 
in 2008.111 The affected family members presented with severe 
hypertension and hypokalemia at young age and in contrast to 
FH-I aldosterone could not be suppressed by dexamethasone. 
FH-III appeared to be caused by a mutation in the KCNJ5-
gene, encoding for the G-protein-activated inward rectifier 
potassium channel Kir3.4.112 This mutation results in the loss 
of K+-selectivity and increased Na+ conductance, leading to 
membrane depolarization of the zona glomerulosa cell with 
subsequent opening of voltage-dependent calcium channels 
and activation of the calcium-signaling pathway (Figure 6). 
Several other mutations in the KCNJ5 gene causing FH-III, not 
always accompanied by a severe phenotype as described for 
the first cases, have been reported.113 In addition to the germ-
line mutations causing FH-III, somatic KCNJ5 mutations, re-
sulting in loss of the selectivity filter of Kir3.4 channel, have 
been identified in surgically removed aldosterone-producing 
adenomas (APAs). These mutations are present in ≤47% in 
APAs from Western populations and ≤65% from a Japanese 
population.95 In addition, several other less frequently occur-
ring somatic mutations in 2 members of the P-type ATPase 
gene family (ATP1A1 and ATP2B3) and in CACNA1D (en-
coding for the voltage-gated Ca2+ channel Ca
v
1.3) have been 
identified (Figure 6).114,115 In adrenal glomerulosa cells, muta-
tions in ATP1A1 result in inappropriate depolarization, muta-
tions in ATP2B3 in decreased intracellular calcium clearance, 
and mutations in CACNA1D in increased Ca2+ influx. In 308 
APAs, negative for KCNJ5 mutations, 5.2% somatic muta-
tions in ATP1A1 and 1.6% mutations in ATP2B3 have been 
identified.95 CACNA1D mutations may occur in ≤11% of 
APAs.116 Interestingly, KCNJ5 mutations are common in APAs 
resembling the cortisol-secreting cells of the zona fasciculata, 
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whereas mutations in P-type ATP-ases and CACNA1D have 
been found in small zona glomerulosa cell APAs.115 These 
genotype–phenotype correlations might hopefully be of clini-
cal use in the near future.
Aldosterone and Resistant Hypertension
Resistant hypertension is defined as uncontrolled hyperten-
sion, despite therapy with 3 drugs, including a diuretic, or BP 
elevations requiring ≥4 drugs for control with an estimated 
prevalence of 10% to 15% of hypertensive patients treated.117 
PA, because of its high prevalence, can underlie resistant hy-
pertension, but also in patients without PA, BP control was 
lower in patients with an elevated ARR and higher aldoste-
rone levels.118 That aldosterone plays a role in resistant hy-
pertension is supported by trials showing that addition of MR 
blockers to usual antihypertensive treatment can sometimes 
produce pronounced BP reductions.119 In an open-label study, 
addition of spironolactone 25 to 100 mg per day to 175 pa-
tients with true resistant hypertension to existing antihyper-
tensive therapy reduced ambulatory BP by 16/9 mm Hg.120 
The mechanism of the BP-lowering effect of MR antagonists 
in resistant hypertension is incompletely understood because 
indices of aldosterone excess, such as low renin or high ARR 
or a low serum potassium, do not predict the response to aldo-
sterone receptor blockers.121 Spironolactone-mediated inhibi-
tion of central sympathetic nervous system activity has been 
proposed as one of the mechanisms.122 Furthermore, reduction 
of vascular stiffness and improvement of endothelial function 
by blockade of vascular MRs may be involved.
Protective Arms of the RAAS: Can We Expect 
New RAAS Drugs?
All current RAAS blockers interfere with the renin–ACE–
AT1 receptor–aldosterone axis. Aldosterone synthase inhibi-
tors are being considered an alternative for MR antagonists,123 
but such drugs would obviously also interfere with this path-
way. Three new RAAS pathways have been discovered in 
the last 2 decades, which might be of interest for future drug 
development: (1) AT2 receptor stimulation, (2) stimulation of 
ACE2-Ang-(1–7)-Mas receptor signaling, and (3) modula-
tion of angiotensin III and IV signaling. In addition, drugs are 
being developed which block the RAAS plus an additional 
hormonal system, for example, combined AT1 receptor block-
ers/neprilysin inhibitors, which prevent the degradation of na-
triuretic peptides (by neprilysin) and combined AT1 receptor/
endothelin-1 receptor antagonists. Their discussion is beyond 
the scope of this review.
AT2 Receptor Stimulation
As discussed earlier, the AT2 receptor is generally considered 
to have effects that are opposite to those of the AT1 recep-
tor. Its presumed endogenous ligands are Ang II, Ang III, 
Ang IV, and Ang-(1–7) in order of highest to lowest affinity 
(Figure 1).124 Ang III seems to be the preferred agonist for 
AT2 receptors.125–127 For reasons that are still unclear, AT2 
receptor-mediated vasodilation is best detected under partial 
AT1 receptor blockade, and the same may apply to its natri-
uretic, antifibrotic, and anti-inflammatory effects in the kid-
ney.125,128–130 AT2 receptor KO mice display an increased BP, 
worsened pressure-natriuresis, increased baroreflex sensitiv-
ity, increased responsiveness to hypertensive stimuli (NO 
synthase inhibition), and decreased cardiac and vascular AT1 
receptor expression.131–133 AT2 receptor overexpression shows 
the opposite.134 It therefore seemed logical to develop specific 
AT2 receptor agonists.
Currently, 4 candidate drugs for clinical development have 
been identified, namely the peptidergic agonists β-Tyr4-Ang 
II, β-Ile5-Ang II, and LP2-3 and the nonpeptide agonist 
Compound 21 (C21).130,135 β-Tyr4-Ang II and β-Ile5-Ang II 
are Ang II analogues in which the Tyr4 and Ile5 α-amino acid 
Figure 6. Mutations in ion channels (encoded by the genes KCNJ5, ATP1A1, CACNA1D, and ATP2B3) of the adrenal glomerulosa 
cell that have recently been linked to excessive aldosterone production. Normally, AT1 receptor activation induces depolarization 
as a result of inactivation of the potassium channel Kir3.4 and Na+,K+-ATPase. Such depolarization triggers Ca2+-influx via voltage-
gated Ca2+ channels (Cav1.3), and the resultant rise in intracellular Ca
2+ activates the aldosterone synthase gene CYP11B2. Ca2+-ATPase 
subsequently removes Ca2+ from the cell. KCNJ5 mutations affect the selectivity of the Kir3.4, now also allowing Na+ conductance. 
Similarly, mutations in ATP1A1 result in loss of pump activity and strongly reduced affinity for potassium, thereby increasing intracellular 
Na+. Increased Na+ levels cause depolarization, even in the absence of AT1 receptor stimulation. Mutations in CACNA1D facilitate Ca
2+ 
influx, whereas mutations in ATP2B3 hamper its removal from the cell, thus both elevating intracellular Ca2+. This activates CYP11B2 
transcription.
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residues have been replaced by β-amino acids, that is, amino 
acids containing an additional methylene group.130 This results 
in an almost complete loss of AT1 receptor affinity, a modest 
(≈5- to 15-fold) decrease in AT2 receptor affinity and an in-
creased stability. Both peptide agonists caused weak, AT2 re-
ceptor-mediated, NO-dependent vasorelaxation in the mouse 
aorta. In addition, β-Ile5-Ang II lowered BP in SHR during 
coinfusion with candesartan.130
LP2-3 is cyclic Ang-(1–7) (see below) with a d-lysine 
N-terminal extension.135 Although it inhibits pathological re-
modeling of lung, cardiac, and vascular tissue in a model of 
hyperoxia-induced neonatal pulmonary dysplasia,135 there is 
currently no proof of its claimed AT2 receptor agonistic activ-
ity. Much more is known about C21, which is expected to en-
ter the clinical phase of development this year.136 Confusingly, 
despite the wealth of data on AT2 receptor-mediated vaso-
dilation, C21 has either no effect on BP or even increases 
BP.129,136,137 The latter may relate to the fact that, for instance 
in SHR, AT2 receptors become AT1 receptor-like (ie, constric-
tor), whereas at exceptionally high doses, C21 also activates 
AT1 receptors.21,137 In vitro, C21 has a weak vasodilator effect, 
particularly observed during AT1 receptor blockade, at con-
centrations above its Kd.138 In fact, because such effects were 
also observed in vessels of AT2 receptor KO mice, it has been 
proposed that C21 has pleiotropic effects; its ability to block 
vasoconstriction to nonangiotensin constrictors further con-
firmed this view.137 In summary, although C21 does not seem 
to be an appropriate antihypertensive drug, the antifibrotic and 
anti-inflammatory effects of AT2 receptor stimulation warrant 
alternative indications, including Marfan’s syndrome.31
Because AT2 receptors also stimulate neurite outgrowth, 
thereby facilitating pain,139 a recent clinical trial has investi-
gated to what degree AT2 receptor antagonists might be ap-
plied in neuropathic pain. Indeed, already after 3 weeks, such 
drugs reduced pain in patients with postherpetic neuralgia.140 
Whether this outcome affects the future application of AT2 re-
ceptor agonists cannot yet be said.
ACE2-Ang-(1–7)-Mas receptor Axis
Ang-(1–7), mainly produced from Ang II by ACE2 (Figure 1), 
opposes AT1 receptor-mediated effects via its binding to the 
Mas receptor.141 Yet, it also binds AT2 receptors and, at high 
concentrations, even acts as a partial AT1 receptor agonist.142 
A plethora of beneficial cardiovascular effects has been de-
scribed for Ang-(1–7) in the past 25 years. These include 
protection against heart failure, natriuretric, antithrombotic, 
antihypertrophic, antifibrotic, and antiarrhythmic effects, at-
tenuation of plaque formation, and amelioration of metabolic 
syndrome-related vascular dysfunction.129,143 It has weak va-
sodilator effects, which have not uniformly been confirmed. 
Ang-(1–7) also stimulates the production of endothelial pro-
genitor cells (and tube formation thereof), but simultaneously 
inhibits tube formation by adult EC.129,143 The circumstances 
under which the BP-lowering effects of Ang-(1–7) have been 
investigated varied widely (species, models, cotreatment with 
RAAS blockers/NO synthase inhibitors, salt intake) so that 
even now it cannot be stated with certainty that Ang-(1–7) is 
an antihypertensive agent. Similarly, although ACE2 over-
expression does lower BP, this may be simply because of its 
capacity to degrade Ang II (rather than its generation of Ang-
(1–7)).144 Even more worryingly, the putative ACE2 activators 
1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-
methylphenyl) sulfonyl oxy]-9H-xanthene-9-one (XNT) and 
diminazene were recently shown to act fully independently 
from either ACE2 or Ang-(1–7), thus questioning whether 
their in-vivo effects have anything to do with this pathway.145
Despite these controversies, stimulation of the ACE2-Ang-
(1–7)-Mas receptor axis might still be an interesting therapeu-
tic option. In view of the rapid breakdown of Ang-(1–7) (as 
well as its AT1 receptor agonistic properties at high concentra-
tions), alternative strategies have been developed. These are 
oligosaccharide (hydroxypropyl β-cyclodextrin)-encapsulated 
Ang-(1–7), Ang-(1–7) peptide stabilization by thioether 
bridging (creating so-called cyclic Ang-(1–7)), NorLeu3-
Ang-(1–7), the peptide drug CGEN856S, and the nonpeptide 
drug AVE0991.129,146 Cyclodextrin-encapsulated Ang-(1–7), 
AVE0091, and CGEN856S have shown BP-lowering effects 
in hypertensive animals, whereas the other agonists have not 
been tested yet in such a setting. Clearly, much more work 
is needed before these drugs can enter the clinic, although 
NorLeu3-Ang-(1–7) has been used clinically to treat foot ul-
cers in diabetic patients.147
Blockade of Ang III and Ang IV
As discussed earlier, Ang III is believed to act as an AT2 recep-
tor agonist, for example, in the kidney and vessel wall. Yet, in 
the brain, it has been proposed to be the preferred AT1 receptor 
agonist, thus causing hypertension.148 On this basis, amino-
peptidase A inhibitors (which block the conversion of Ang II 
to Ang III) are now being developed, which act exclusively 
in the brain. Indeed, RB150 (4,4′-dithio[bis(3S)-aminobutyl 
sulfonic acid]) is a prodrug that, after crossing the blood–brain 
barrier, is converted to the aminopeptidase A inhibitor EC33 
((3S)-3-amino-4-sulfanyl-butane-1-sulfonic acid).149 RB150 
can be delivered orally and has already shown antihyperten-
sive and cardioprotective properties in animal models, so that 
it is now under evaluation in a phase Ib clinical study.150
To what degree the aminopeptidase N product of Ang III, 
that is, Ang IV, has a function in BP regulation remains un-
clear. At high (micromolar) concentrations, it binds to AT1 
and AT2 receptors, resulting in both constrictor and relax-
ant effects, the former possibly involving endothelin-1.151,152 
However, the relevance of these observations, given its low 
(femtomolar) concentrations in vivo, is questionable. Instead, 
high potency effects of Ang IV may rather involve its binding 
to insulin-regulated aminopeptidase (IRAP), also known as 
the AT4 receptor (please note that AT3 receptors do not exist, 
the 4 refers to Ang IV).153 Unfortunately, even this concept 
has recently been challenged,154 leaving as a final option the 
observation that Ang IV binds with high affinity to AT1 recep-
tors that are constitutively active, that is, that already display 
activity without agonist binding.155 Until today the physiologi-
cal relevance of this phenomenon is unknown.
Conclusions
Tissue angiotensin generation depends on kidney-derived 
renin and hepatic angiotensinogen, occurs extracellular, and 
is followed by rapid AT receptor binding and internalization. 
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Locally generated Ang II affects the constrictor/relaxant bal-
ance, vascular remodeling, and inflammation. Tissue angio-
tensin generation does not necessarily run in parallel with 
angiotensin generation in the circulation, and this explains 
why the beneficial effects of RAAS blockers cannot be simply 
explained on the basis of changes in the circulating RAAS. 
Sex, ethnicity, salt intake, genetic variation, and the use of 
antihypertensive drugs determine the degree of RAAS ac-
tivity, and although in general high RAAS activity (as evi-
denced by high plasma renin levels) would be supportive for 
the application of RAAS blockers, the interindividual RAAS 
component variation is such that it is impossible to exactly 
define high or low renin levels that warrant the choice for a 
certain RAAS blocker. Too much RAAS blockade yields ef-
fects that can be expected when removing Ang II/aldosterone 
(hypotension, hyperkalemia, renal dysfunction), and thus the 
goal should be to obtain optimal instead of maximal RAAS 
blockade, guided by regularly measuring BP, potassium, and 
creatinine. Aldosterone unexpectedly has a wide range of ex-
trarenal effects, among others in EC and VSMC, and these are 
not necessarily all mediated via the MR. Together with the 
many mutations that have recently been discovered in genes 
encoding for proteins that control sodium, potassium, and cal-
cium ion homeostasis in adrenal cells (with strong resultant 
effects on aldosterone synthesis), this explains the revived 
interest in drugs that block aldosterone, for example, in resis-
tant hypertension. In addition, the discovery of the relaxant, 
protective arms of the RAAS, involving AT2 and Mas receptor 
stimulation, may yield new drugs that can be applied in the 
future on top of the existing RAAS blockers in patients with 
cardiovascular and renal disorders.
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